Search

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

… Friday, November 2, 2012 Summary Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer. Ping Chi , a member of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program (HOPP) , is a laboratory investigator

Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.

… Monday, December 16, 2024 Four people who were successfully treated for rectal cancer in a clinical trial at Memorial Sloan Kettering are seen posing outdoors with the trial’s two principal investigators. Four people who were successfully treated for rectal cancer in a clinical trial at Memorial Sloan

Pacientes con cáncer de recto vieron cómo sus tumores desaparecían en un ensayo clínico que incluía inmunoterapia en el Memorial Sloan Kettering Cancer Center, sin someterse a cirugía, radiación ni quimioterapia.

… Monday, December 16, 2024 Four people who were successfully treated for rectal cancer in a clinical trial at Memorial Sloan Kettering are seen posing outdoors with the trial’s two principal investigators. Four people who were successfully treated for rectal cancer in a clinical trial at Memorial Sloan

The cBioPortal for Cancer Genomics, developed by computational biologists at MSK more than a decade ago, provides valuable data on the genetic makeup of tumors for the broader cancer community.

… Thursday, May 20, 2021 Every month, more than 30,000 scientists from institutions around the world tap into the cBioPortal for Cancer Genomics , which contains data on tens of thousands of tumors. Sharing information to expedite discoveries and improving patient care everywhere have been the key goals

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce Jason Lewis, PhD, has been elected as a Fellow of the National Academy of Inventors (NAI), a prestigious honor recognizing individuals who have demonstrated innovation and made tangible contributions to the advancement of technology and society.

… Thursday, December 11, 2025 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce Jason Lewis, PhD, has been elected as a Fellow of the National Academy of Inventors (NAI) , a prestigious honor recognizing individuals who have demonstrated innovation and made tangible contributions to the

Peter T. Meinke will take the Tri-I TDI into the next phase of growth.

… Tuesday, June 12, 2018 Peter T. Meinke, PhD, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). A pioneering academic-industry collaboration, the Tri-I TDI is designed to expedite

Memorial Sloan Kettering Cancer Center has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research.

… Monday, September 23, 2013 Memorial Sloan Kettering Cancer Center has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research . The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research. The winners are Simon J.

… Wednesday, May 27, 2009 Goals, Milestones, and Transitions Faculty Member Stephen Nimer and First-Year Student Armine Matevossian Faculty Member Stephen Nimer and First-Year Student Armine Matevossian The goal of our graduate program is to increase the pace of translating laboratory findings into clinical

Memorial Sloan Kettering Cancer Center (MSK) and New York Cancer & Blood Specialists (NYCBS), one of the fastest-growing community oncology practices in the nation, today announced plans to open a 39,000 sq ft facility in Brooklyn, New York, in early 2023.

… Thursday, June 2, 2022 Memorial Sloan Kettering Cancer Center (MSK) and New York Cancer & Blood Specialists (NYCBS), one of the fastest-growing community oncology practices in the nation, today announced plans to open a 39,000 sq ft facility in Brooklyn, New York, in early 2023. The new facility will

Cancer immunologist Andrea Schietinger, PhD, of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award. Dr. Schietinger was selected as a winner for her groundbreaking work in immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy. A total of 55 New Innovator Awards were given out by the NIH this year.

… Thursday, October 5, 2017 Cancer immunologist Andrea Schietinger, PhD , of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award . Dr. Schietinger was selected as a winner for her